Post by
Viking2233 on Oct 27, 2024 7:57pm
Stockholm Conference
Some interesting facts for consideration. The Stockholm conference runs from November 4 to 13. This is a 9 day conference that we are presenting at. I wonder who we are sending and how many days will be there for?
Now what really caught my attention is how this conference is being advertised. " Europe's Premiere Partnering Event"
The key word is "Partnering"
Now we have been dosing for 8 months at 5 Turkish sites for our Metablok AKI phase 2 trial. The trial is slated to dose 240 patients. Where are we in this trial? Have we dosed 50? 100? 240? Have we had a signal? We are dosing Metablok at 4 times the dosage in previous phase 2 trial? Are we close to the end of this trial or has it ended? Are we shifting to the next phase of this long process?
We have raised $1,000,000 in new capital over the past 3 months and the last raise had a 4 month lock up period.
We have a second phase 2 Pontiac trial using our re-purposed Cilastatin drug on 900 patients. The University of Calgary is conducting this trial with Government funding. There is zero risk for Arch. Cilistatin is a re-purposed drug from the 1980's, FDA approved, safe and used in the past. This is a very big deal. There are so many applications where it can be utilized.
Now back to our Stockholm Conference which is being advertised as Europe's Premiere Partnering Event. So are we to assume we are securing a partner/Investor with deep pockets or potential buyer??
This my fellow investors is very big. Arch management is extremely conservative and calculated. They are presenting the Arch story for a reason!
Something big is brewing!!